GSK - GlaxoSmithKline plc

NYSE - Nasdaq Real Time Price. Currency in USD
38.93
-0.04 (-0.10%)
As of 11:34AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close38.97
Open39.37
Bid38.970 x 2900
Ask38.980 x 3200
Day's Range38.92 - 39.50
52 Week Range34.89 - 42.36
Volume1,432,738
Avg. Volume3,732,064
Market Cap94.37B
Beta (3Y Monthly)0.50
PE Ratio (TTM)39.24
EPS (TTM)0.992
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.96 (5.04%)
Ex-Dividend Date2018-11-15
1y Target Est43.84
Trade prices are not sourced from all markets
  • 3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss
    Motley Fool3 hours ago

    3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss

    Results from a few clinical trials reading out in 2019 could make it a year to remember.

  • Why Should You Hold Genpact (G) Stock in Your Portfolio?
    Zacksyesterday

    Why Should You Hold Genpact (G) Stock in Your Portfolio?

    Strong domain expertise in business analytics, digital and consulting services to boost demand for Genpact's (G) offerings.

  • Reuters2 days ago

    PRESS DIGEST- Financial Times - Jan 22

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Mike Ashley enters the bidding for HMV https://on.ft.com/2CEtw7F ...

  • The Drugs Aren't Working Yet for GlaxoSmithKline
    Bloomberg2 days ago

    The Drugs Aren't Working Yet for GlaxoSmithKline

    Philip Hampton has overseen plenty of change in that brief time. For CEO and Hampton appointee Emma Walmsley, a change at the top should bring fresh pressure to deliver. Hampton came aboard at a time of mounting investor discontent with the old regime of chairman Chris Gent and CEO Andrew Witty.

  • The Drugs Aren't Working Yet for GlaxoSmithKline
    Bloomberg2 days ago

    The Drugs Aren't Working Yet for GlaxoSmithKline

    Philip Hampton has overseen plenty of change in that brief time. For CEO and Hampton appointee Emma Walmsley, a change at the top should bring fresh pressure to deliver. Hampton came aboard at a time of mounting investor discontent with the old regime of chairman Chris Gent and CEO Andrew Witty.

  • The Wall Street Journal2 days ago

    [$$] GSK Chairman Hampton to Leave

    GlaxoSmithKline said Monday that Chairman Philip Hampton intends to step down after nearly four years in the role with a successor yet to be found.

  • Financial Times2 days ago

    [$$] Taxi for Just Eat CEO as Uber and Deliveroo serve up competition

    Diners will not wait one-and-a-half hours for a takeaway to deliver, according to YouGov research. So why did takeaway food service Just Eat think investors might wait one-and-a-half years? That was the ...

  • GSK Chairman Hampton to step down ahead of split
    Reuters2 days ago

    GSK Chairman Hampton to step down ahead of split

    The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer (PFE.N) would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.

  • GSK Chairman Hampton to step down ahead of split
    Reuters2 days ago

    GSK Chairman Hampton to step down ahead of split

    The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer (PFE.N) would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.

  • Financial Times2 days ago

    [$$] GSK chairman to step down ahead of break-up

    The search for Sir Philip’s successor will take up to nine months, according to someone familiar with the process, who said he would have completed about five years on the board when he eventually stepped down. On his watch there had been “a lot of change that needed to happen”.

  • TheStreet.com7 days ago

    Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

    It's not too late to late to buy the banks, even after today's monster run, Jim Cramer told his Mad Money viewers Wednesday. In short, the banks are making more money than ever, Cramer said, and they're doing it with more technology and fewer employees. The fact is, shares of Goldman should never have been that low in the first place, Cramer said.

  • GSK Foundation awards UNC $1M
    American City Business Journals12 days ago

    GSK Foundation awards UNC $1M

    A $1.13 million grant to UNC-Chapel Hill will support Triangle-area students entering STEM studies and the workforce.

  • Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
    Zacks12 days ago

    Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

    Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

  • New Strong Sell Stocks for January 11th
    Zacks12 days ago

    New Strong Sell Stocks for January 11th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • 4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
    Zacks12 days ago

    4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

    Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

  • Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
    Zacks13 days ago

    Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting

    Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journals14 days ago

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

    The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

  • Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
    Zacks15 days ago

    Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

    Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

  • TheStreet.com15 days ago

    Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline

    In this daily bar chart of GSK, below, we can see a choppy sideways trading range for GSK the past year. The daily On-Balance-Volume (OBV) line has turned to the upside signaling that buyers of GSK have turned more aggressive. In the middle of December we can see that the Moving Average Convergence Divergence (MACD) oscillator crossed to the upside for a cover shorts buy signal.

  • GlaxoSmithKline to look for early-stage assets - CEO
    Reuters15 days ago

    GlaxoSmithKline to look for early-stage assets - CEO

    Britain's biggest drugmaker is also likely to evaluate licensing deals and would continue to invest in early-stage HIV treatments, CEO Emma Walmsley said at the JP Morgan healthcare conference in San Francisco. Walmsley said the company had extensive plans for its experimental drug to treat multiple myeloma, which targets a protein called BCMA, adding that it could be launched by 2020. On the company's portfolio of cancer medicines, she said GlaxoSmithKline had almost doubled the size of its immuno-oncology pipeline over the past few months.

  • Reuters15 days ago

    GlaxoSmithKline to look for early-stage assets - CEO

    GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker's chief executive officer said on Tuesday. Britain's biggest drugmaker is also likely to evaluate licensing deals and would continue to invest in early-stage HIV treatments, CEO Emma Walmsley said at the JP Morgan healthcare conference in San Francisco. Walmsley said the company had extensive plans for its experimental drug to treat multiple myeloma, which targets a protein called BCMA, adding that it could be launched by 2020.

  • Crowded Cancer Space Triggers Big M&A Deals: More in Store?
    Zacks15 days ago

    Crowded Cancer Space Triggers Big M&A Deals: More in Store?

    Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.

  • 3 Companies You Don't Realize You Rely On Every Day
    Motley Fool15 days ago

    3 Companies You Don't Realize You Rely On Every Day

    You use their products. Should you own their stock, too?

  • Cramer: Drug stocks are an even better way than tech to invest in innovation
    CNBC16 days ago

    Cramer: Drug stocks are an even better way than tech to invest in innovation

    Jim Cramer says leading drugmakers are innovating more than ever before and many of their stocks are worth owning.